• HSD102 Preferences of Nurses for Attributes of Pediatric Hexavalent Vaccines in the United Kingdom

    Dec 1, 2023, 00:00

  • CO99 Real-Life Effectiveness of Ibrutinib in Chronic Lymphocytic Leukemia

    Dec 1, 2023, 00:00

  • P40 Man Versus Machine: Can AI-Assisted Technology be Used to Support the Development of Economic Models?

    Dec 1, 2023, 00:00

  • EE346 Evaluating the Economic Burden of Osteoporosis in the United States: Insights from a MEPS-Based Analysis

    Dec 1, 2023, 00:00

  • EE298 Process and Results of the Third Update of the Dutch Guideline for Economic Evaluations in Healthcare: Evolution Instead of Revolution

    Dec 1, 2023, 00:00

  • HPR90 Global Disparities in P4P Programs for Diabetes Care: A Comprehensive Analysis

    Dec 1, 2023, 00:00

  • PCR125 Unmet Needs of People with Multiple Sclerosis: Findings for an Improvement of the Patient Journey in Portugal

    Dec 1, 2023, 00:00

  • EE27 Risk, Use, and Cost of Infection-Related Hospitalization of Individuals With Alzheimer’s Disease or Dementia

    Dec 1, 2023, 00:00

  • HTA24 Are the Hurdles Too High for Access to Gene Therapies in the UK?

    Dec 1, 2023, 00:00

  • PCR191 Assessing Quality of Care in Haemophilia Using a Value-Based Healthcare Approach

    Dec 1, 2023, 00:00

  • MSR22 Standardized Contrasts Across Trials in Individual Patient Data Meta-Analysis With Time-to-Event Outcomes

    Dec 1, 2023, 00:00

  • PCR244 Core Oncology Outcome Strategies: Do They Offer an Opportunity for Simplicity and Consistency, or Pose a Risk to Comprehensive Understanding of Patient Experiences?

    Dec 1, 2023, 00:00

  • PCR59 Self-Reported Health Status and Its Predictors Among People with Diabetes in France

    Dec 1, 2023, 00:00

  • EE751 Economic Evaluation of Hepatitis B Vaccination Programme in Finland

    Dec 1, 2023, 00:00

  • PCR216 Patient-Driven Outcome Selection (PDOS): A Patient-Focused Approach for Selecting Outcomes Using Patient-Generated Data

    Dec 1, 2023, 00:00

  • EE666 Cost-Effectiveness of Duvelisib Versus the Bendamustine Plus Rituximab Regimen for Relapsed/Refractory Follicular Lymphoma Patients in China

    Dec 1, 2023, 00:00

  • PT40 Epidemiology and Burden of Illness of Lupus in Children by Form of Lupus: A Retrospective Longitudinal National Hospital Claims Study in France

    Dec 1, 2023, 00:00

  • EE277 Assessing the Cost-Effectiveness of Semaglutide 2.4 Mg Injection for Chronic Weight Management in Portugal

    Dec 1, 2023, 00:00

  • EE630 The Economic Burden of Obesity in 4 Selected South-Eastern European Countries: Healthcare Resource Use and Costs Associated with Obesity-Related Comorbidities

    Dec 1, 2023, 00:00

  • RWD140 Quality of Electronic Health Records: Encountering Misclassification

    Dec 1, 2023, 00:00

  • PCR154 How and Why Do Multimorbid Patients Adhere to Their Medications? A Qualitative Study Looking Beyond the Risk-Benefit Scale

    Dec 1, 2023, 00:00

  • HSD122 A Systematic Review on Equal Access to Treatment for Hearing Loss in Chile: Do All People Have the Same Opportunities to Receive Appropriate Treatment?

    Dec 1, 2023, 00:00

  • EE710 The Environmental, Healthcare, and Societal Impact of Asthma Pathway in the UK: A Cost-of-Illness Study

    Dec 1, 2023, 00:00

  • EE621 Cost-Effectiveness Analysis of iGlarLixi Compared With Basal Bolus Insulin Regimen in Triple Metabolic Goal in Type 2 Diabetes Mellitus in Latin America

    Dec 1, 2023, 00:00

  • EE560 A Comparison of Time-Driven Activity-Based Costs for Patients and Caregivers Receiving Intravitreal Treatments for Neovascular Age-Related Macular Degeneration

    Dec 1, 2023, 00:00

  • HTA106 What Are the Main Drivers for Decision-Making Regarding the Incorporation of a Healthcare Technology By CONITEC in Brazil? A Study in the Cardiovascular, Oncology, and Respiratory Fields

    Dec 1, 2023, 00:00

  • EE673 Cost-Effectiveness Analysis of Pembrolizumab for First-Line Treatment in Patients With Persistent, Recurrent, and Metastatic Cervical Cancer in the United States: Results From the Final Analysis of Trial

    Dec 1, 2023, 00:00

  • EE297 Healthcare Resources Utilization Among Sectors in Saudi Arabia

    Dec 1, 2023, 00:00

  • CO138 Outcomes and Health-Related Costs of Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Brazilian Public Health System

    Dec 1, 2023, 00:00

  • EE680 Axicabtagene Ciloleucel as Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain: A Cost-Effectiveness Analysis

    Dec 1, 2023, 00:00

  • HPR119 Assessing Health Policies in Turkiye: Expert Insights on Current Challenges and Policy Recommendations from Written Motions

    Dec 1, 2023, 00:00

  • RWD163 The Economic Burden of Cutaneous Malignant Melanoma in Gree Analysis of Real-Word Health Insurance Data

    Dec 1, 2023, 00:00

  • SA67 Considerations for Including Different Routes of Administration in Network Meta-Analysis: A Comprehensive Review

    Dec 1, 2023, 00:00

  • HSD43 Survey Research Using PRO Data in Clinical Practi Lessons Learnt from the Nordic Countries

    Dec 1, 2023, 00:00

  • HTA188 The Potential Value of Health Technologies Postponing Total Knee Replacements While Increasing Patients’ Quality of Life

    Dec 1, 2023, 00:00

  • HTA211 Requirements for Economic Evaluations for Health Technology Assessment Submissions across Different Countries

    Dec 1, 2023, 00:00

  • MSR86 Use of Data Linkage for the Evaluation of Medical Devices: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • EE636 Cost-Minimization Analysis of Delafloxacin Versus Standard of Care for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Jordan

    Dec 1, 2023, 00:00

  • PCR100 Vascular Access Adverse Events: A Comprehensive Literature Review and Comparative Analysis

    Dec 1, 2023, 00:00

  • HTA65 Economic Evaluation of Medical Devices By the French National Authority (2014-2022): Where Do We Stand?

    Dec 1, 2023, 00:00

  • HTA287 Impact of the 2020 Update of the French Guidelines for Economic Evaluation on the Economic Opinions Issued By the Economic Evaluation and Public Health Committee (CEESP)

    Dec 1, 2023, 00:00

  • CO24 Daratumumab in Combination with Lenalidomide and Dexamethasone Improves Survival in Newly Diagnosed Transplant-Ineligible Multiple Myeloma: A Parametric Network Meta-Analysis in a United Kingdom Setting

    Dec 1, 2023, 00:00

  • EE523 Is Dismissing Intervention Development Costs a Fallacy? a Case Study of a Digital Health Intervention E-MAT

    Dec 1, 2023, 00:00

  • PCR258 Baseline Demographic and Clinical Characteristics of Patients with Plaque Psoriasis Treated with Brodalumab in the Canadian Real-World Setting: Results from the Care Study

    Dec 1, 2023, 00:00

  • CO23 How Immunotherapies Have Altered the Future of Cancer Treatment: Patients Living Longer, Healthier Lives

    Dec 1, 2023, 00:00

  • EPH28 Burden of Chronic Lymphocytic Leukemia in the United States: A Review of Literature

    Dec 1, 2023, 00:00

  • EPH71 Tendencies in Hospital Burn Care for Children in Germany

    Dec 1, 2023, 00:00

  • PCR78 Establishing Meaningful Change Thresholds for EORTC QLQ-CLL17 Domain Scores: An Analysis Based on the TRANSCEND CLL 004 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Dec 1, 2023, 00:00

  • HTA167 Another Hurdle in Anticancer New Drug Listing in Korea—Setting the Reimbursement Scope

    Dec 1, 2023, 00:00

  • HTA139 Uptake of Early Heath Technology Assessment in the United Kingdom: A Literature Review of Empirical Studies

    Dec 1, 2023, 00:00

  • Study Approaches

    Dec 1, 2023, 00:00

  • HTA7 Exploring the Predictive Accuracy of Treatment Waning Methods: An Analysis of Pembrolizumab across Six Oncology Indications

    Dec 1, 2023, 00:00

  • EPH62 Impact of Ethnicities on the Risk of Type 2 Diabetes in Women With a History of Gestational Diabetes: Results of a Systematic Review and Meta-Analysis

    Dec 1, 2023, 00:00

  • MT9 The Role of HTA Agencies in Relation to Medical Technologies: A Discourse Analysis

    Dec 1, 2023, 00:00

  • HTA365 Comparison of the Use of Real-World Evidence for Clinical Effectiveness in HTA Pre- and Post- Introduction of the NICE Framework

    Dec 1, 2023, 00:00

  • EE236 The Economic Impact of Third Line Chronic Phase Chronic Myeloid Leukemia Treatment in Greece From a National Payer Perspective

    Dec 1, 2023, 00:00

  • HTA127 No Half Measures: Health Inequalities in Technology Appraisal

    Dec 1, 2023, 00:00

  • HSD15 Investigating the Impact of Early Versus Late Diagnosis in Fabry Disease on Healthcare Resource Utilization and Associated Costs in Greece

    Dec 1, 2023, 00:00

  • EE507 Pre-Progression Health State Utility Values From the TALAPRO-2 Clinical Trial in Patients With Metastatic Castration-Resistant Prostate Cancer Unselected for DDR Mutations

    Dec 1, 2023, 00:00

  • EE267 Cost-Effectiveness of a Web-Based Interactive Therapeutic Education Platform: Evidence From a Randomized Clinical Trial for Patients With End-Stage Renal Disease

    Dec 1, 2023, 00:00

  • CO16 Effect of Daratumumab on Pneumonia in Patients with Multiple Myeloma Using Population Based Real-World Data

    Dec 1, 2023, 00:00

  • HTA202 Guideline for Costing in Italian Economic Evaluations: A Proposal of the ISPOR Italy Rome Chapter

    Dec 1, 2023, 00:00

  • CO53 A Review of Treatment Effect Modifiers and/or Prognostic Factors Included in Unanchored Indirect Treatment Comparisons (ITCs) Involving Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

    Dec 1, 2023, 00:00

  • EE76 End-of-Life Cost and Characteristics of Acute Myeloid Leukemia Decedents: A National Study From 2011-2020

    Dec 1, 2023, 00:00

  • EPH127 School Environment and Mental Health State in Brazilian Adolescents – Evaluating Public Policy Opportunities

    Dec 1, 2023, 00:00

  • MSR14 Unleashing the Potential of Artificial Intelligence in Genomic Biomarker Testing for Precision Oncology: A Scoping Review

    Dec 1, 2023, 00:00

  • CO84 Characterization of Long-COVID Phenotypes and Associated Clinical Phenotypes in Administrative Claims Data

    Dec 1, 2023, 00:00

  • HTA118 Estimands in Health Technology Assessments: Methodological Considerations and Recommendations

    Dec 1, 2023, 00:00

  • PCR157 Assessment of Health State Utilities for Invasive Pneumococcal Disease, Pneumonia, and Acute Otitis Media in Young Children

    Dec 1, 2023, 00:00

  • HPR187 Is the Older Adult Subgroup of the Rare Disease Population Marginalized on Purpose? an Analysis of Equity Issues Encountered By the (OLDER) Rare Disease Population

    Dec 1, 2023, 00:00

  • EE158 Cost Effectiveness and Budget Impact of Patient Blood Management in a Turkish State Hospital

    Dec 1, 2023, 00:00

  • MT51 Does Current Reimbursement Drive the Adoption of Computer-Aided Applications to Increase the Adenoma Detection in Colonoscopies – a Provider-Based Impact Model for Germany, France, and Italy

    Dec 1, 2023, 00:00

  • EE587 A Systematic Scoping Review to Identify Challenges in the Economic Evaluation of Prognostic and Predictive Companion Diagnostics in Personalized Medicine: The Radioval Study

    Dec 1, 2023, 00:00

  • EE251 The Impact of Cesarean Birth Complications on Maternal and Infant Health in the World and Turkiye

    Dec 1, 2023, 00:00

  • HSD39 Treatment Pathway and Unmet Needs of Mantle Cell Lymphoma Patients: An Exploratory Study from Portugal

    Dec 1, 2023, 00:00

  • EE294 Public Health Impact and Cost-Effectiveness of Recombinant Zoster Vaccination Among 50 Years Old or Older in Austria

    Dec 1, 2023, 00:00

  • EE379 Economic Evaluation of Nubeqal for the Treatment of Adult Patients With Non-Metastatic Castration Resistant Prostate Cancer in the Mexican Context

    Dec 1, 2023, 00:00

  • EPH202 Current Policy, Clinical and Economic Environment of Eye Care and Vision Health in Bulgaria

    Dec 1, 2023, 00:00

  • EE213 Presenting Expected Net Loss Curves to Better Communicate Decision Uncertainty in Cost Effectiveness Analysis

    Dec 1, 2023, 00:00

  • EE103 Cost-Effectiveness Analysis of Single-Inhaler Triple Therapy (FF/UMEC/VI) in COPD Using the Fulfil Trial: China Medical Insurance System Perspective

    Dec 1, 2023, 00:00

  • HPR196 Loss of Exclusivity (LOE): Impact Analysis across Europe-5 and Select Nordic Countries

    Dec 1, 2023, 00:00

  • PCR210 Effectiveness of a Decision Aid for Parents/Caregivers of Children Needing Enteral Support

    Dec 1, 2023, 00:00

  • CO62 Network Meta-Analysis (NMA) of Immuno-Oncology (IO) Treatments for First-Line (1L) Advanced or Metastatic Melanoma

    Dec 1, 2023, 00:00

  • HTA30 Behavioural Structured Expert Elicitation: A Case Study to Inform Hospitalisation Due to Respiratory Syncytial Virus in the UK

    Dec 1, 2023, 00:00

  • HPR184 Social Determinants of Health (SDoH) and Other Predictors in Treatment Initiation with CDK4/6 Inhibitors in Medicare Patients with HR+/HER2– Metastatic Breast Cancer (MBC)

    Dec 1, 2023, 00:00

  • SA33 The Role of Artificial Intelligence in Decoding the Placebo Response - Implications for Clinical Research and Practice

    Dec 1, 2023, 00:00

  • EE93 Real-World Cost-Effectiveness of Asfotase Alfa for Treatment of Patients with HPP in England

    Dec 1, 2023, 00:00

  • HSD67 How Can a Digital Twin Help Achieve Technical Efficiency? an Application to the French Medical Genomics Pilot Sequencing Platform Auragen

    Dec 1, 2023, 00:00

  • HTA354 Cross Analysis of HAS Conclusions Amongst Products with an Economic Opinion Posted in 2022

    Dec 1, 2023, 00:00

  • HSD84 Financial Hardship from Neglected Tropical Diseases: A Systematic Literature Review and Meta-Analysis

    Dec 1, 2023, 00:00

  • EPH123 A Machine Augmented Systematic Literature Review: Prevalence of Coinfections in COVID-19 Patients During Early and Late Pandemic Periods

    Dec 1, 2023, 00:00

  • CO102 Physician Reported Treatment Attributes Considered in First-Line and Perceptions Around Bruton Tyrosine Kinase Inhibitor (BTKi) Treatments in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in the US

    Dec 1, 2023, 00:00

  • CO151 Association of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists With the Risk of Developing Dementia in People With Type 2 Diabetes Mellitus

    Dec 1, 2023, 00:00

  • HSD98 Patient Characteristics and Treatment Patterns in Patients with Advanced Psoriasis in Specialty Care Settings in Finland

    Dec 1, 2023, 00:00

  • HTA262 Cost-Utility Analysis of Influenza Vaccination with a High Dose Quadrivalent Vaccine for the Brazilian Elderly Population in the Private Healthcare Sector

    Dec 1, 2023, 00:00

  • EPH69 Disease Burden of Patients With Antibiotic-Resistant Bacteria (Extended-Spectrum Beta-Lactamase or Carbapenem-Resistant Enterobacteriaceae) in Korea

    Dec 1, 2023, 00:00

  • EE549 Systematic Review of the Cost Effectiveness of Newborn Screening for Severe Combined Immunodeficiency

    Dec 1, 2023, 00:00

  • EE206 Clinical and Economic Evaluation of Atezolizumab + Vemurafenib + Cobimetinib Combination in Treatment of Adult Patients with Metastatic Braf-Positive Melanoma

    Dec 1, 2023, 00:00

  • EE11 Budget Impact of Patient Blood Management in the Cardiovascular Surgery Department of a Turkish Private Hospital

    Dec 1, 2023, 00:00

  • MSR83 An Overview of “Multinma” Package: Multilevel Network Meta-Regression

    Dec 1, 2023, 00:00

  • MSR162 The Curse of Data Maturity in Observational Studies: Practical Advice from Protocol Development to Interpretation of Results

    Dec 1, 2023, 00:00

  • HTA150 Health Technology Assessment of Domiciliary Invasive Ventilation for Adults With Spinal Cord Injuries

    Dec 1, 2023, 00:00

  • PCR108 Pilot Testing the Hungarian Version of Online Elicitation of Personal Utility Functions Tool for Valuing EQ-5D-5L Health States

    Dec 1, 2023, 00:00

  • HTA119 Mapping a Path to Standardized Evidence Quality Tools Across EU HTA Agencies and NICE: Is EU Joint Clinical Assessment Guidance Falling Behind?

    Dec 1, 2023, 00:00

  • CO60 Predicting Treatment Effects from Surrogate Endpoints in First-Line (1L) Metastatic Castration-Resistant Prostate Cancer (MCRPC)

    Dec 1, 2023, 00:00

  • HTA220 Incorporating Environmental Sustainability Considerations into National HTA Assessments: A Landscape Review

    Dec 1, 2023, 00:00

  • MSR34 Feasibility of Using Finnish Real-World Data to Build an External Control Arm for the Factor Xia Inhibitor Asundexian Pacific-AF Trial

    Dec 1, 2023, 00:00

  • PCR167 Persistence and Adherence to Insulin Treatment in Chinese Patients with Type 2 Diabetes: A Real-World Study

    Dec 1, 2023, 00:00

  • HTA170 Assessing the Impact of the NICE Methods Review on Rare Diseases

    Dec 1, 2023, 00:00

  • EE678 Time and Cost Savings from Adopting an Alternative Dosing Schedule with Pembrolizumab for Patients with Advanced Melanoma in Greece

    Dec 1, 2023, 00:00

  • EE632 Identification of Health State Utility Values for Health Economic Models: Empirical Testing of Alternative Search Methods

    Dec 1, 2023, 00:00

  • PCR193 Health State Utilities Associated with X-Linked Retinitis Pigmentosa in the United Kingdom

    Dec 1, 2023, 00:00

  • OP29 A Comparative Study of Patient Safety Culture Between 2013 and 2019 at a University Hospital in a Rural Area in Japan

    Dec 1, 2023, 00:00

  • CO12 5 Years of Real-World Data on the Use of Cladribine Tablets for the Treatments of Multiple Sclerosis in Portugal

    Dec 1, 2023, 00:00

  • Real-World Data Information Systems

    Dec 1, 2023, 00:00

  • EE438 Cost-Effectiveness of Nirsevimab Against Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV LRTD) in the US Birth Cohort

    Dec 1, 2023, 00:00

  • RWD17 Methodology for the Development of a Data Collection Tool

    Dec 1, 2023, 00:00

  • HTA208 Paradigm Shift or Incremental Change? Real-World Evidence for Health Technology Assessment: A Critical Appraisal

    Dec 1, 2023, 00:00

  • RWD8 Study of the Mental Health of Pharmacists During Wartime in Ukraine

    Dec 1, 2023, 00:00

  • RWD171 Healthcare Resource Utilization and Cost of Renal Replacement Therapy in Brazil: A Five-Year Procedure-Level Analysis

    Dec 1, 2023, 00:00

  • HSD124 Treatment Patterns in Pediatric Patients with Atopic Dermatitis

    Dec 1, 2023, 00:00

  • MSR146 Proportional Hazards in Survival Analysis: A Review of the Variation in Determining and Presenting PH in NICE STAs

    Dec 1, 2023, 00:00

  • PCR158 The Uniqueness and Overlap of the EQ-HWB and the EQ-5D-5L in Four Diseases, Healthy Subjects, and Caregivers

    Dec 1, 2023, 00:00

  • CO105 A Retrospective Study Characterizing Age at Loss of Ambulation Among Patients With Friedreich Ataxia Using Health Administrative Claims Data in the United States

    Dec 1, 2023, 00:00

  • EE604 Cost-Effectiveness Analysis of Single-Inhaler Triple Therapy (FF/UMEC/VI) in COPD Using the Impact Trial: China Medical Insurance System Perspective

    Dec 1, 2023, 00:00

  • HTA158 Exploring Efficiency of Living Systematic Literature Review (SLR) Tool for Submissions of Clinical Evidence to National Institute for Health and Care Excellence (NICE) by Combining Interventional and Real-World Evidence (RWE)

    Dec 1, 2023, 00:00

  • Using Artificial Intelligence to Enhance Efficiency in Systematic Reviews and Meta-Analyses

    Dec 1, 2023, 00:00

  • P44 Seeing it in the Flesch: Comparing Readability Between AI-Generated and Human-Written Plain-Language Abstracts

    Dec 1, 2023, 00:00

  • CO29 Real-World Benefit of Ataluren Treatment in Milestones Not Related to Ambulatory Function in Nonsense Duchenne Muscular Dystrophy Versus Standard of Care

    Dec 1, 2023, 00:00

  • CO86 Comparing Factors Associated With First and Recurrent Psychiatric Hospitalizations in Adult Patients With Major Depressive Disorder Using Cox Proportional Hazard Model and Extensions

    Dec 1, 2023, 00:00

  • HSD10 The Hospital Care Pathway of Patients Treated By Axi-Cel and Tisa-Cel between 2018 and 2021 in Fran A National Study Based on the Comprehensive Inpatient Stays Database

    Dec 1, 2023, 00:00

  • HTA178 Using Mixed-Methods Development-Focused HTA and Npv Calculations to Guide Further Investment and RD: A Case Study on Establishing the Value Proposition for Biosensor-Integrated Self-Reporting Arteriovenous Grafts

    Dec 1, 2023, 00:00

  • HPR44 Regional Inequalities in Access to Specialized Healthcare in the Brazilian Unified Health System

    Dec 1, 2023, 00:00

  • EE516 Cost-Utility Analysis (CUA) in Chronic Lymphocytic Leukemia (CLL): Is COVID-19’s Impact on National Life Tables Important to Consider?

    Dec 1, 2023, 00:00

  • CO32 Validation of a Scoring Algorithm for the Clinician-Reported Outcome ”Prurigo Activity and Severity (PAS)’’ Tool: Results Based on Clinical Studies of Dupilumab in Adults with Prurigo Nodularis

    Dec 1, 2023, 00:00

  • PCR182 Patient Preferences for Tumor-Agnostic Therapies: Qualitative Insights and Challenges

    Dec 1, 2023, 00:00

  • HTA177 The Safety and Effectiveness of Root Membrane Technique (Socket Shield Technique)

    Dec 1, 2023, 00:00

  • CO132 A Real-World Evidence Analysis of the Impact of Patient-Physician Sex Concordance on Cancer Treatment Practices and Outcomes

    Dec 1, 2023, 00:00

  • RWD80 Labor Impact in Patients with Rheumatoid Arthritis (RA) Treated with Advanced Therapies

    Dec 1, 2023, 00:00

  • MT43 Does Real-World Evidence Play a Role in Decision-Making by HTA Bodies for Medical Technologies?

    Dec 1, 2023, 00:00

  • EE484 Multinational Real-World Data in Transplant Patients with Refractory/Resistant Cytomegalovirus Infection Enhance Cost-Effectiveness Modelling Outcomes

    Dec 1, 2023, 00:00

  • HTA186 Accelerating Access to Medical Technologies: An Overview of the NICE Early Value Assessment Pilot Project in the UK

    Dec 1, 2023, 00:00

  • RWD101 Intravitreal Therapies and Their Patterns of Use in Lombardy Region

    Dec 1, 2023, 00:00

  • PCR272 Qualitative Research to Explore Womens Experience of Vasomotor Symptoms and Evaluate the Suitability of Patient-Reported Outcomes

    Dec 1, 2023, 00:00

  • CO173 Outcomes, Treatment Pattern, and Related Cost of Late-Stage Non-Small Cell Lung (NSCLC) Cancer in Taiwan

    Dec 1, 2023, 00:00

  • RWD77 Real-World Data Analysis Showing a Significant Improvement in Glycemic Control of People with T2D in Poland When Using a Blood Glucose Meter Connected to a Mobile Health App

    Dec 1, 2023, 00:00

  • EPH59 An Evidence Gap Analysis of the Epidemiology and Burden of Obstructive Hypertrophic Cardiomyopathy

    Dec 1, 2023, 00:00

  • CO71 Faricimab Versus Standard of Care in Naive Neovascular Age-Related Macular Degeneration Patients: An Indirect Treatment Comparison Using Individual Level Data

    Dec 1, 2023, 00:00

  • HTA140 The in Need of Medicines Fund: Analysis of NICE Technology Appraisals to Explore Barriers to Managed Access Via the IMF

    Dec 1, 2023, 00:00

  • HPR134 Ethical Considerations in Pay-for-Performance Programs for Diabetes

    Dec 1, 2023, 00:00

  • HPR201 Lessons from the COVID-19 Vaccines Taskforce

    Dec 1, 2023, 00:00

  • CO168 A Propensity Score-Based Comparison of Tepotinib Versus Immunotherapy with/without Chemotherapy, Using Real-World Data in Previously Untreated Met Exon 14 (METEX14) Skipping Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2023, 00:00

  • OP22 Content Analysis of Drug Recall Announcements in Saudi Arabia: Between 2016 and 2022

    Dec 1, 2023, 00:00

  • EE411 Cost-per-Responder Analysis of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis

    Dec 1, 2023, 00:00

  • HSD99 Analysis of Evidence Information About Herbal Medicinal Products and Its Use for Postgraduate Pharmacy Trainings in Ukraine

    Dec 1, 2023, 00:00

  • MSR53 Flexsurv Methods to Estimate Cure: An Exploration of Methods for Modelling Cure

    Dec 1, 2023, 00:00

  • EPH82 Real-World Outcomes in Patients with Resected Non-Small Cell Lung Cancer (NSCLC) Receiving (NEO)Adjuvant Treatment in Germany: An I-O Optimise Analysis

    Dec 1, 2023, 00:00

  • MSR111 Causal Inference and Statistical Considerations for Indirectly Comparing Time-to-Event Endpoints for Treatments with Different Starting Points for Outcome Assessment in Resectable NSCLC

    Dec 1, 2023, 00:00

  • HPR35 Modelling the Effects of Smoking on Healthy Life Expectancy (HLE) in England

    Dec 1, 2023, 00:00

  • HPR5 Implementing a Value-Based Payment Model for Patients with Osteoarthritis

    Dec 1, 2023, 00:00

  • EE345 Clinical and Economic Impact Analysis of Viscosupplementation With Hylan G-F 20 Versus Hyaluronic Acid for the Treatment of Knee Osteoarthrosis in Colombia

    Dec 1, 2023, 00:00

  • HTA351 A Targeted Review Exploring How English and German Health Technology Assessment Agencies Differ in Their Appraisal of Digital Health Apps

    Dec 1, 2023, 00:00

  • EPH263 Algorithmic Public Health? The Path Towards AI-Assisted Health Promotion

    Dec 1, 2023, 00:00

  • HTA198 Comparisons of Economic Evaluation Guidelines Between Japan and Six Countries (England, France, Germany, Sweden, Canada and Australia)

    Dec 1, 2023, 00:00

  • EE48 Healthcare Resource Utilization (HCRU), Quality of Life (QoL), and Employment Changes for Early, Middle and Late-Stage People with Amyotrophic Lateral Sclerosis (pALS) in Italy: Results from a Real-World Survey

    Dec 1, 2023, 00:00

  • How Do Patients With Type 2 Diabetes Mellitus Value the Importance of Outcomes? An Overview of Reviews

    Dec 1, 2023, 00:00

  • EE40 Cost-Effectiveness Analysis of Tofacitinib for the Treatment of Active Ankylosing Spondylitis in Greece

    Dec 1, 2023, 00:00

  • P23 Evolving Use of Artificial Intelligence and Machine Learning in Systematic Literature Reviews (SLRs)

    Dec 1, 2023, 00:00

  • PCR8 Perceived Barriers to HIV Prevention and Detection Among Adolescents and Young People, According to Civil Organization Leaders and Health Professionals in Chile

    Dec 1, 2023, 00:00

  • HPR69 Comparison of Price Trends for Medicines Pre- and Post-Early Access in Key Markets (France, UK, Australia)

    Dec 1, 2023, 00:00

  • HTA301 How End of Life Translates to Severity Weighting Under the New National Institute for Health and Care Excellence (NICE) Methodology. A Review of Past Oncology Appraisals

    Dec 1, 2023, 00:00

  • EPH260 Rare Diseases and Kidney Stones: Are Stones in Amino Acid Transport Disorders Special?

    Dec 1, 2023, 00:00

  • CO50 Imminent Recurrent Fracture Risk in Patients with Osteoporotic Fractures: A Nationwide Cohort Study in South Korea

    Dec 1, 2023, 00:00

  • MSR55 How Different Are EQ-5D-Y Values in Asia? a Comparison Study of Four Jurisdictions

    Dec 1, 2023, 00:00

  • HTA359 Market Access of ATMPs in Fran Challenges and Opportunities

    Dec 1, 2023, 00:00

  • EPH132 Epidemiology of Breast and Cervical Cancer in Women of the Colombian Caribbean Region During 2018-2021

    Dec 1, 2023, 00:00

  • RWD22 Economic Burden of Moderate and Severe Hemophilia A and B in Spain, Real-World Evidence Insights from the Cost of Hemophilia in Europe: A Socio-Economic Survey II (CHESS II) Study

    Dec 1, 2023, 00:00

  • HTA114 How Are Companion Diagnostics Evaluated and Reimbursed in Europe? Comparative Analysis of the EU-4 and UK

    Dec 1, 2023, 00:00

  • EE280 The Lean Assessment Process (LAP) Methodology: An Iterative and Multi-Disciplinary Method for Identifying Clinical Needs, Assessing Technology Acceptance, a Precursor for Early Economic Evaluation and Adoption Strategies

    Dec 1, 2023, 00:00

  • PCR83 Fibrodysplasia Ossificans Progressiva (FOP): The Patient Experience

    Dec 1, 2023, 00:00

  • HPR183 Evaluating the Saving Potential of Lenalidomide Before and After Transition to the Reference Price System in Finland

    Dec 1, 2023, 00:00

  • HTA56 Unequal Access of Innovative Drug Products Across Canada

    Dec 1, 2023, 00:00

  • HSD80 Employees Satisfaction Working at Arta General Hospital of Greece

    Dec 1, 2023, 00:00

  • RWD143 Beyond Accuracy: Automated De-Identification of Large Real-World Clinical Text Datasets

    Dec 1, 2023, 00:00

  • PCR58 Social Media Research to Understand Reported Efficacy of GLP-1 RAs for Weight Loss

    Dec 1, 2023, 00:00

  • EE625 Time in Range As Alternative to HBA1C Change in the IQVIA Core Diabetes Model

    Dec 1, 2023, 00:00

  • EE490 Analysis of Access and Avalibility of Low Molecular Heparins for the Treatment of COVID-19 during Wartime in Ukraine

    Dec 1, 2023, 00:00

  • PT4 Patient-Reported Outcomes (PROs) in German AMNOG-Assessments: Impact of Increasing the Response Threshold to 15 %

    Dec 1, 2023, 00:00

  • P20 Matching-Adjusted Indirect Treatment Comparison (MAIC) of Teclistamab Vs Belantamab Mafodotin for the Treatment of Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

    Dec 1, 2023, 00:00

  • EE191 Projecting Costs of Care Burden of Depression Between 2023 and 2032 in Hong Kong: A Time-Inhomogeneous Cohort Markov Model Using Real-World Evidence

    Dec 1, 2023, 00:00

  • EPH232 The Disease Burden and Healthcare Resource Utilization of Gram-Negative Multi-Drug Resistant Bacteria

    Dec 1, 2023, 00:00

  • MSR52 Defining Severity Category Thresholds to Guide Psoriasis Symptoms and Impacts Measure Score Interpretation Using Pooled Data from Three Phase 3 Trials in Plaque Psoriasis

    Dec 1, 2023, 00:00

  • EE6 Expected Value of Perfect Implementation of Icosapent Ethyl (Vazkepa) in Sweden

    Dec 1, 2023, 00:00

  • PCR162 Talking with Teens: Techniques for Building Rapport with Adolescents in Virtual Qualitative Interviews

    Dec 1, 2023, 00:00

  • EE629 The Obesity Burden and Impact of Weight Loss on Saudi Public Payers Using Value of Weight Loss Simulation Model

    Dec 1, 2023, 00:00

  • CO146 Language Model-Based Approach for Extracting Comorbidities and Complications in Fabry Disease Clinical Notes

    Dec 1, 2023, 00:00

  • EE572 Budget Impact Analysis of the Introduction of Endo Arteriovenous Fistula System (WAVELINQ) for Hemodialysis Access Creation in Patients with End-Stage Kidney Disease

    Dec 1, 2023, 00:00

  • HPR86 Reducing Inequity: Does the New EU Pharmaceutical Legislation Address Challenges to Pharmaceutical Access in Central and Eastern Europe?

    Dec 1, 2023, 00:00

  • HSD22 Vaccine Preparation Time, Cost, and Preference Comparison Between Pre-Filled Syringe Formulations and Vaccines That Require Reconstitution: A Targeted Literature Review

    Dec 1, 2023, 00:00

  • MSR37 Validation of the Ibadan Knee/Hip Osteoarthritis Outcome Measure (IKHOAM) Among Patients With Knee Osteoarthritis

    Dec 1, 2023, 00:00

  • EE159 Cost-Effectiveness Analysis of an Adjusted Polygenic Risk Score in Cardiovascular Disease Prevention

    Dec 1, 2023, 00:00

  • EPH87 Real-World Evidence Study on Hemophilia B Treatment with Factor IX and Corresponding Treatment Costs in Finland

    Dec 1, 2023, 00:00

  • HPR112 International Market Access Strategies for Artificial Intelligence-Based Medical Devices: Can We Standardized the Process to Faster Patient Access?

    Dec 1, 2023, 00:00

  • PCR54 Knowledge, Attitudes and Practices of Patients Towards Generics in Greece

    Dec 1, 2023, 00:00

  • EE653 A Health Economic Model to Assess the Effects of Introducing Home Polysomnography for the Diagnosis of Sleep Apnea in Germany

    Dec 1, 2023, 00:00

  • EE420 Cost-Effectiveness of Empagliflozin in Chronic Kidney Disease (CKD) Management in the UK

    Dec 1, 2023, 00:00

  • HSD50 Infantile Vaccination Coverage in Brazil From 2016-2022 – Effects of Pandemic Period in Non-COVID-19 Vaccination

    Dec 1, 2023, 00:00

  • HPR202 The Digital Transformation: How Could Artificial Intelligence (AI) Re-Shape Drug Launch?

    Dec 1, 2023, 00:00

  • HTA163 Setting Treatment Selection Criteria for Breast Cancer From a Clinician Perspective: Is It a Matter of Cost?

    Dec 1, 2023, 00:00

  • PCR118 Cross-Sectional Measurement Properties of the Physical Distancing Scale – COVID-19 (PDS-C19) Self- and Observer-Reported Measure of Physical Distancing Behaviors to Avoid COVID-19 in Adults, Children, and Caregivers

    Dec 1, 2023, 00:00

  • CO68 Gastrointestinal Manifestations and Incontinence Products in the Real World Among Patients with Rett Syndrome in the United States

    Dec 1, 2023, 00:00

  • OP7 Coverage and Equity of a Patient Support Program for Diabetes During the Pandemic Period in a Middle-Income Country

    Dec 1, 2023, 00:00

  • EE102 Economic Burden of Short-Acting Beta-2 Agonist Overuse Among Asthma Patients in Turkiye: A Cost Analysis with Respect to Updated Recommendations of the Global Initiative for Asthma

    Dec 1, 2023, 00:00

  • MSR8 Nesting a Decision Tree into a Markov Model Structure: An Alternative Way of Tracking Movement in a Diagnostic Model

    Dec 1, 2023, 00:00

  • EE538 Hospital Budget Impact of a Lung Suite Navigation Platform to Diagnose and Treat Lung Cancer Patients

    Dec 1, 2023, 00:00

  • HPR107 Bilateral Price Comparison of 50 Particularly Cost-Intensive Drugs – What Is the Impact of Different Reimbursement Rules?

    Dec 1, 2023, 00:00

  • SA78 Active Participation of Children in Health Research: Methods, Experience and Ethical Aspects

    Dec 1, 2023, 00:00

  • P38 Forecasting Emergency Department Waiting Times Using Deep Neural Networks

    Dec 1, 2023, 00:00

  • Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0

    Dec 1, 2023, 00:00

  • SA21 Feasibility Assessment of an Indirect Treatment Comparison (ITC) of Sacituzumab Govitecan (SG) Vs Trastuzumab Deruxtecan (T-DxD) in HR+/HER2– Metastatic Breast Cancer (mBC)

    Dec 1, 2023, 00:00

  • P18 Adjusted Comparison of Teclistamab Versus Real-World Physician’s Choice (RWPC) of Therapy in Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

    Dec 1, 2023, 00:00

  • HSD44 Healthcare Resource Utilization of Severe Eosinophilic Asthma Patients Treated With Benralizumab in Real-Life: Results From the Portuguese BETREAT Study

    Dec 1, 2023, 00:00

  • HSD87 Physician Reported Reasons for Cidp Treatment Choice across 5 European Countries: Results from a Real-World Survey

    Dec 1, 2023, 00:00

  • HTA9 Success Rate of Cancer Drugs Fund Reappraisals

    Dec 1, 2023, 00:00

  • SA58 Approaches to Examine Treatment Adherence and Persistence Using German Claims Data: An Exemplary Analysis Using Oral Therapies for Prostate Cancer

    Dec 1, 2023, 00:00

  • CO87 Lifetime Cumulative Risk of Bone Fracture in Chinese Male Patients with Osteoporosis: A Model Simulation Study

    Dec 1, 2023, 00:00

  • EE448 Exploring Non-Patient Utilities Using Time Trade-Off Exercises in the UK General Population

    Dec 1, 2023, 00:00

  • EE724 Inside CKD: Projecting the Population Level Economic Burden of Chronic Kidney Disease According to Urine Albumin-to-Creatinine Ratio (uACR) Categories

    Dec 1, 2023, 00:00

  • EE147 "I'll Live Less, You'll Live Better, Let's Make It Count": A Qualitative Exploration of Drivers Barriers for Sacrificing Remaining Life Expectancy to Restore Relatives to Full Health in Time Trade Off Exercises

    Dec 1, 2023, 00:00

  • EPH176 Comorbidities Among Individuals at Risk to Develop Severe Form of COVID-19 in Case of Sars-Cov-2 Infection

    Dec 1, 2023, 00:00

  • EPH14 Burden of Respiratory Syncytial Virus Infection in Germany: A Systematic Review

    Dec 1, 2023, 00:00

  • HTA71 Bridging the Gap: Exploring the PICO Vs Estimand Frameworks in EU Health Technology Assessment (HTA)

    Dec 1, 2023, 00:00

  • MSR80 AI-Enabled Risk of Bias Assessment of RCTs in Systematic Reviews: A Case Study

    Dec 1, 2023, 00:00

  • EPH205 Inside CKD: Predicting the Clinical and Economic Burden of Chronic Kidney Disease in Belgium

    Dec 1, 2023, 00:00

  • HTA73 Health Technology Assessment (HTA) Timelines Analysis in the Post-COVID Era: Comparison of HTA Process Duration in the First Half (H1) of 2023 to H1 2022

    Dec 1, 2023, 00:00

  • Reflecting Parameter Uncertainty in Addition to Variability in Constrained Healthcare Resource Discrete Event Simulations: Worth Going the Extra Mile or a Road to Nowhere?

    Dec 1, 2023, 00:00

  • EE359 Cost-Effectiveness of Pembrolizumab + Chemotherapy Versus Cetuximab-Containing Regimens ‘Extreme’ and ‘TPEx’, for R/M SCCHN Patients with a CPS between 1 and 19, in Italy

    Dec 1, 2023, 00:00

  • PT23 Is It Possible to Estimate the Welfare Economic Loss to Society of Not Having Value-Based Differential Pricing for Multi-Indication Pharmaceuticals: An Empirical Analysis in Denmark, Norway, and Sweden

    Dec 1, 2023, 00:00

  • EE440 Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Indian Adults Aged ≥60 Years

    Dec 1, 2023, 00:00

  • HTA104 Data on Patient-Reported Outcomes Is Not a Prerequisite for Achieving an Additional Benefit in German Early Benefit Assessment of New Medicinal Products Approved for Dermatological Diseases

    Dec 1, 2023, 00:00

  • EPH93 Progression From Cutaneous to Systemic Lupus Erythematosus: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • MT33 Cost-Effectiveness Analysis of Watchman FLX Left Atrial Appendage Closure in Patients with Non-Valvular Atrial Fibrillation

    Dec 1, 2023, 00:00

  • MSR73 Methods for Incorporating External Eviden A Comparison of Their Impact on Extrapolations and Uncertainty Estimates Using a Melanoma Case-Study

    Dec 1, 2023, 00:00

  • EPH125 A Systematic Literature Review and Meta-Analysis on the Disease Burden of Chikungunya

    Dec 1, 2023, 00:00

  • HPR100 Orphan Drugs in Algeria and Six Other Countries: A Cross Comparison Study

    Dec 1, 2023, 00:00

  • EE377 Budget Impact Analysis of Implementing a Breast Cancer Screening Program in Bulgaria

    Dec 1, 2023, 00:00

  • HTA184 Review of HTA Evaluation for Gene Therapies and Their Future Implications in Europe

    Dec 1, 2023, 00:00

  • EPH196 Prevalence of GI Comorbidities by Age Group Among Patients With Rett Syndrome: An Analysis of Coded EHR and Pharmacy Data and Clinical Notes

    Dec 1, 2023, 00:00

  • HPR37 Squaring the Circle? Leveraging Early Access / Compassionate Use Pathways to Provide Market-Specific Real-World Evidence Before Launch

    Dec 1, 2023, 00:00

  • EE651 Incremental Cost per Remission in Patients With Rheumatoid Arthritis Who Had Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Colombia

    Dec 1, 2023, 00:00

  • PCR254 Building a COA Strategy in Chronic Rhinosinusitis with or Without Nasal Polyps: Patient Experiences and Clinical Outcome Assessments from the Literature

    Dec 1, 2023, 00:00

  • EPH161 Epidemiology Landscape and Impact of Obesity: Multi-Country Results from the Impact-O Study

    Dec 1, 2023, 00:00

  • PCR214 Patient Voice in Pharmaceutical Company: The Case of Patient Committee in Brazil

    Dec 1, 2023, 00:00

  • EE340 Cost-Effectiveness Analysis of Molnupiravir Against Standard Care for Treating Mild to Moderate COVID-19 Infection in Singapore.

    Dec 1, 2023, 00:00

  • PCR263 Design of a Patient-Informed Chronic Kidney Disease (CKD) Experience Interview Guide: Learnings From DISCOVER CKD

    Dec 1, 2023, 00:00

  • RWD120 Analysis of the Impact of National Medical Insurance Negotiation Policy on the Accessibility of Anti-Cancer Drugs in a City in China

    Dec 1, 2023, 00:00

  • EE626 Budget Impact Analysis (BIA) of Adopting Real-Time Continuous Glucose Monitoring (rt-CGM) vs Intermittent-Scanning Continuous Glucose Monitoring (is-CGM) in Patients With Type 1 Diabetes on Insulin Therapy (PWT1D) in Italy

    Dec 1, 2023, 00:00

  • RWD47 Non-Motor Symptoms Burden and Quality of Life in Patients with Parkinson’s Disease (PD)

    Dec 1, 2023, 00:00

  • EE66 Cost Effectiveness Analysis of Pembrolizumab as First-Line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer in Greece

    Dec 1, 2023, 00:00

  • HTA352 The Significance of Literature Reviews in the Process of Decision-Making by the Haute Autorité De Santé

    Dec 1, 2023, 00:00

  • RWD7 Graphical Representation of Real-World Data for Analysing Infection Outbreaks Within a Tertiary Hospital Setting: A Data-Driven Approach

    Dec 1, 2023, 00:00

  • PCR201 Estimating the Respiratory Syncytial Virus (RSV) Health Utility Values for Older Adults and Their Caregivers in the Japanese Population: A Time Trade-Off (TTO) Study

    Dec 1, 2023, 00:00

  • RWD36 Immunoglobulin Use in France 2015 to 2022–Real-World Data From the French Claims Database

    Dec 1, 2023, 00:00

  • EE254 Budget Impact of Telemonitoring (TM)-Enabled Care of Obstructive Sleep Apnea Hypoanpnea Syndrome (OSAH) in the UK

    Dec 1, 2023, 00:00

  • PT22 Exploring Reimbursement Disparities: A Comparative Study of Pharmaceutical Access in Hong Kong and Mainland China

    Dec 1, 2023, 00:00

  • EE138 Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Singaporean Adults Aged ≥18 Years

    Dec 1, 2023, 00:00

  • HTA193 Benefits Not Captured in the Quality-Adjusted Life Year Calculation: What Role Do They Play in the National Institute for Health and Care Excellence's Updated Decision-Making Process?

    Dec 1, 2023, 00:00

  • MT18 Endovascular Management of Iliac and Aorto-Iliac Aneurysms and Impact on Morbidity/Mortality in Fran A French National Insurance Claims Database Analysis (SNDS)

    Dec 1, 2023, 00:00

  • MT37 Clinical Utility of Circulating Tumor Cell (CTC) Enumeration-Based Liquid Biopsy and HER2 CTC Assessment in Patients with Metastatic Breast Cancer: Overview of Current Available Data and Interventional Trials

    Dec 1, 2023, 00:00

  • RWD170 Investigating the Association between Pain Burden and Multimorbidity Among United States Adults with Pain

    Dec 1, 2023, 00:00

  • PT16 Impact of Data Maturity on the Estimation of the within-Trial Hazard Function: An Example from Metastatic Castration Resistant Prostate Cancer

    Dec 1, 2023, 00:00

  • EE182 Costs and Health Impact of Wastewater Surveillance to Guide Respiratory Syncytial Virus Prophylaxis in Canada, Compared to Clinical Surveillance

    Dec 1, 2023, 00:00

  • EPH190 Clinical Characteristics and Treatment Patterns of Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Mexico

    Dec 1, 2023, 00:00

  • RWD98 Health Care Resource Use and Costs of Hemophilia A in France

    Dec 1, 2023, 00:00

  • MSR124 Improving the Efficiency of Using the Guyot Algorithm to Construct Pseudo Individual Patient Data From Kaplan-Meier Survival Curves: Standardized Guidance and Data Preparation

    Dec 1, 2023, 00:00

  • PCR41 The Impact of Moderate to Severe Chronic Hand Eczema and the Effect of Improved Clinical Symptoms on Work Productivity Loss: Data from the DELTA 1 and DELTA 2 Phase 3 Trials

    Dec 1, 2023, 00:00

  • RWD44 Utilization of Short-Term and Long-Term Disability, and Workers' Compensation in Employees with Major Depressive Disorder Compared with Employed Controls

    Dec 1, 2023, 00:00

  • EE500 An Overview of Systematic Literature Review of Economic Evaluation of Treatment on Patients With Alzheimer's Disease and Related Dementia

    Dec 1, 2023, 00:00

  • HTA243 Guidelines for Incorporating the Societal Perspective and Wider Societal Benefits in Health Technology Assessment

    Dec 1, 2023, 00:00

  • CO100 Regular Laboratory Checks for Ileostomy Patients After Surgery Are Not Performed Comprehensively, but Could Result in Better Health Outcomes

    Dec 1, 2023, 00:00

  • RWD108 Real-World Data and Real-World Evidence Terminology Harmonization: Evidence Gaps and Future Steps

    Dec 1, 2023, 00:00

  • CO51 Safety Profile of Approved Alzheimer's Medication By USFDA

    Dec 1, 2023, 00:00

  • HSD105 Pharmacists' Intervention in Access to Therapeutical Innovation in Portuguese Hospitals

    Dec 1, 2023, 00:00

  • EE270 Predicting Persistent Severe Acute Kidney Injury (AKI) Using the Urinary C-C Motif Chemokine Ligand 14 Biomarker (CCL14). Cost-Utility Analysis in Spain and the UK

    Dec 1, 2023, 00:00

  • HSD123 Environmental Impact of Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in the Netherlands

    Dec 1, 2023, 00:00

  • MT61 Differences and Similarities of Health Economic Evaluation for Medical Technologies By HTA Bodies

    Dec 1, 2023, 00:00

  • HTA83 Economic Evaluations in Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Challenges for Health Technology Assessment (HTA) Submissions

    Dec 1, 2023, 00:00

  • EPH241 Labor-Market Affiliation Among Danish Migraine Patients Discontinuing Triptan Treatment—A Register-Based Study

    Dec 1, 2023, 00:00

  • EE413 Economic and Humanistic Burden of Chronic Spontaneous Urticaria: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • EE562 What Is More Valuable Than Optimal Resource Use? The Development of Interactive Tool Visualizing the Costs and Time Consumption Related to Diabetic Macular Edema’s Intravitreal Treatments in Finland

    Dec 1, 2023, 00:00

  • RWD5 Body Fatness Associations with Cancer: Retrospective Cohort Study from a Brazilian Health Management Organization (RWE)

    Dec 1, 2023, 00:00

  • RWD116 The Economic Burden of Moderate to Severe Rheumatoid Arthritis (RA) in Spain: Interim 6-Month Results

    Dec 1, 2023, 00:00

  • HTA181 How Can Health Technology Assessment Help in Addressing Drug Repurposing Challenges? A Conceptual Framework

    Dec 1, 2023, 00:00

  • HSD38 From Unpersonalized to Personalized Breast Follow-up in Clinical Practice in the Netherlands: Will Artificial Intelligence Make a Difference?

    Dec 1, 2023, 00:00

  • HPR165 Financial-Based Managed Entry Agreements for Drugs in Romania: From Simple to Complex

    Dec 1, 2023, 00:00

  • EE563 Cost-Effectiveness of the PPARγ Modulator N-Acetyl-Ged-0507-34-Levo (NAC-GED 5%) Versus Benzoyl Peroxide-Adapalene for Moderate to Severe Acne

    Dec 1, 2023, 00:00

  • EE566 Systematic Literature Review for Utility Data in Haemophilia

    Dec 1, 2023, 00:00

  • MT6 Companion Diagnostics’ Launch and Market Access Landscape: Who Are the Trend Setters and Late Adopters?

    Dec 1, 2023, 00:00

  • PCR246 Measuring Treatment Preferences for Patients with Pulmonary Arterial Hypertension (PAH); A Discrete Choice Analysis to Identify Scale Heterogeneity

    Dec 1, 2023, 00:00

  • EE325 Healthcare Resource Use and Costs Associated with Obesity and Obesity-Related Complications in Saudi Arabia

    Dec 1, 2023, 00:00

  • HPR133 Analysis of Information Content on the Web Services About Antihypertensive Medicines in Ukraine

    Dec 1, 2023, 00:00

  • CO184 Exploring the Relationship Between Surrogate and Long-Term Outcomes in Lysosomal Storage Diseases: A Targeted Literature Review

    Dec 1, 2023, 00:00

  • CO137 Health Outcomes of ALK-Inhibitors in Non-Small Cell Lung Cancer in Real Clinical Practice

    Dec 1, 2023, 00:00

  • PT31 A Time Series Analysis of Immune Checkpoint Inhibitors Use in Italian Population: 2017-2022

    Dec 1, 2023, 00:00

  • PCR179 The Socio-Economic and Health-Related Quality of Life Impact of Myasthenia Gravis (MG) in Greece

    Dec 1, 2023, 00:00

  • PCR271 Employing Episodic Future Thinking to Reduce the Distortion of Time Preference in Time Trade-Off Valuation

    Dec 1, 2023, 00:00

  • CO59 Matching-Adjusted Indirect Comparison (MAIC) of Nivolumab + Relatlimab (NIVO+RELA) Vs. BRAF/MEK Inhibitors for First-Line Treatment of BRAF-Mutant Advanced/Metastatic Melanoma (AMEL)

    Dec 1, 2023, 00:00

  • PCR37 The Impact of Leber’s Heredity Optic Neuropathy (LHON) on Quality of Life (QoL): A Systematic Literature Review (SLR)

    Dec 1, 2023, 00:00

  • EE184 Lessons Learned from Model-Based Economic Evaluations of COVID-19 Treatments Under Pandemic Circumstances: Results from a Systematic Review

    Dec 1, 2023, 00:00

  • HTA245 UK Mechanisms to Address Rare Disease Challenges: Does the UK Go Far Enough?

    Dec 1, 2023, 00:00

  • HTA295 Insights From Economic Evaluations in Emerging Infection Diseases in Fran Focus on COVID-19

    Dec 1, 2023, 00:00

  • RWD174 Using Real-World Evidence to Quantify Hospital Costs of Subcutaneous Implantable Cardioverter-Defibrillator Infections in the US

    Dec 1, 2023, 00:00

  • EE605 Methodological Acceptability of the Economic Analyses Assessed by the HAS in 2022

    Dec 1, 2023, 00:00

  • EE113 The Use of Ferric Carboxymaltose for Pregnant and Postpartum Women in Brazil: Estimation of Target Poputation and Budget Impact Analysis from the Public Health Care System Perspective

    Dec 1, 2023, 00:00

  • PCR235 Drivers of Treatment Preferences in High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) Patients: Qualitative Interviews to Inform a Patient-Preference Study

    Dec 1, 2023, 00:00

  • PCR219 Hungarian Population Norms for the 15D Generic Preference-Accompanied Health Status Measure

    Dec 1, 2023, 00:00

  • HPR15 Review and Evaluation of Health Equity Considerations in Health Technology Assessments in Cystic Fibrosis

    Dec 1, 2023, 00:00

  • EE432 Propel® Technology – A Budget Impact Analysis in the Italian Context

    Dec 1, 2023, 00:00

  • HSD111 Real-World Treatment Patterns of Ankylosing Spondylitis

    Dec 1, 2023, 00:00

  • MT10 Clinical and Economic Impact of Point-of-Care (POC) Molecular Testing in Patients Presenting With Viral Respiratory Symptoms: A Systematic Literature Review (SLR)

    Dec 1, 2023, 00:00

  • SA56 Treatment Patterns of Advanced Egfr-Positive Non-Small Cell Lung Cancer (NSCLC) in Latin America

    Dec 1, 2023, 00:00

  • EE449 Uncertainty Around HRQoL Values Is Under-Reported: Are We Misleading Decision Makers?

    Dec 1, 2023, 00:00

  • HTA247 Focus on Two Years of Economic Opinions on Orphan Drug: What Are the Specific Features?

    Dec 1, 2023, 00:00

  • EE246 Is It Possible to Reduce the Costs of Care for Pediatric Patients With Hemophilia A and Inhibitors in Trinidad Tobago?

    Dec 1, 2023, 00:00

  • HTA86 Factors Affecting Time to Reimbursement of Novel Anticancer Drugs in Ireland

    Dec 1, 2023, 00:00

  • HTA171 The Use of Qualitative Methods in the NICE HST Deliberative Process

    Dec 1, 2023, 00:00

  • EE408 Pharmacoeconomic Analysis of Abrocitinib in Patients with Severe Atopic Dermatitis Versus Systemic Treatments in Spain

    Dec 1, 2023, 00:00

  • PCR149 Determination of Ranges of HiSQOL Scores Defining Clinically Meaningful Within-Patient Improvement Thresholds and Severity Levels

    Dec 1, 2023, 00:00

  • EE317 Microsimulation Model in Obesity: A Feasibility Study Using Object-Oriented C++ Code

    Dec 1, 2023, 00:00

  • EE442 An Economic Evaluation of Universal Childhood Varicella Vaccination in Ireland

    Dec 1, 2023, 00:00

  • SA79 Opportunities and Challenges for Decentralized Clinical Trials: European Health Technology Assessment Perspective

    Dec 1, 2023, 00:00

  • EE683 The Impact of Tumor Treating Fields (TTFields) Therapy Usage on Cost-Effectiveness: An Analysis of the Incremental Cost-Effectiveness Ratio (ICER)

    Dec 1, 2023, 00:00

  • HPR74 Analysis of the Guangdong-Hong Kong-Macau Greater Bay Area Urgent-Use Medicine Scheme—An Opportunity for Early Access in Mainland China

    Dec 1, 2023, 00:00

  • EPH29 Estimating the Incidence and Characteristics of Female Patients in Norway With Early Breast Cancer Who Are at High Risk of Disease Recurrence

    Dec 1, 2023, 00:00

  • HTA235 Comparative Narrative Review of Oncology Value Assessment Frameworks: Enfortumab Vedotin (EV) for Treatment of Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)

    Dec 1, 2023, 00:00

  • SA63 Planning Phase 3 Clinical Trials More Efficiently Using an Evidence-Mapping Approach

    Dec 1, 2023, 00:00

  • EPH103 Estimating the Burden of Vaccine-Preventable Respiratory Diseases Without Vaccination Alternatives in Europe: What's Going on in Spain and Germany?

    Dec 1, 2023, 00:00

  • PCR151 Health Related Quality of Life (HRQOL) Among Patients with Transthyretin Amyloidosis (ATTR): A Systematic Literature Review

    Dec 1, 2023, 00:00

  • RWD87 Retrospective Observational Study of Patients with Metastatic Merkel Cell Carcinoma (mMCC) Using the Caraderm Database Linked to the French National Health Data System (SNDS)

    Dec 1, 2023, 00:00

  • HPR211 Turkiye Healthcare Inflation Review between 2017 to 2022

    Dec 1, 2023, 00:00

  • EPH104 Human Papilloma Virus (HPV) Vaccination: Financial Impact and Recommendations

    Dec 1, 2023, 00:00

  • RWD83 Epidemiological Characterization of the Current Patient Population of Multiple Sclerosis Patients Enrolled in a Patient Registry for Interferon-Beta 1a SC in Portugal

    Dec 1, 2023, 00:00

  • EE391 The Economic Burden of Varicella Among Children in Fran A Societal Perspective

    Dec 1, 2023, 00:00

  • EE87 Liquid Metformin for Pediatric Patients with Metabolic Syndrome at Risk of Developing DMT2: Cost-Effectiveness Analysis in Mexican Public Health Institutions

    Dec 1, 2023, 00:00

  • EE397 Determinants of Higher Cost and Inpatient Hospitalization Among Patients with AL Amyloidosis

    Dec 1, 2023, 00:00

  • EE643 Cost-Effectiveness of Universal Asymptomatic Preoperative SARS-CoV-2 PCR Screening: A Cost-Utility Analysis

    Dec 1, 2023, 00:00

  • HPR154 When Could a Managed Entry Agreement Create a Win-Win-Win Situation - Exploring the Window of Opportunity

    Dec 1, 2023, 00:00

  • HPR105 Profitability in the Global Pharmaceutical Industry: A Contested Space

    Dec 1, 2023, 00:00

  • HPR128 Addressing Bias in Health Applications: A Path Towards Health Equity

    Dec 1, 2023, 00:00

  • EE29 Clinical and Economic Impact of Pre-Exposure Prophylaxis With Tixagevimab+Cilgavimab in 2022 in Switzerland to Protect Immunocompromised Individuals

    Dec 1, 2023, 00:00

  • MT75 Analysis of Manufacturer and Negotiated Price Differential of Digital Health Applications (DIGA) in Germany

    Dec 1, 2023, 00:00

  • EE707 Modelling the Cost Effectiveness and Budget Impact of Uterine Botulinum Toxin Injections in Severe Dysmenorrhoea: A France Perspective

    Dec 1, 2023, 00:00

  • HSD132 Analysis of Factors Affecting Medication Adherence in Patients with Hypertension in South Korea

    Dec 1, 2023, 00:00

  • SA28 Evaluation of Disease Epidemiology, Comorbidities, Treatment Patterns, and Healthcare Resource Utilization of Alopecia Areata in United Arab Emirates: A Retrospective Claims Database Study

    Dec 1, 2023, 00:00

  • PCR72 How to Achieve Comprehensive Care for Breast Cancer? Challenges in Chile from the Voice of Patients

    Dec 1, 2023, 00:00

  • EE148 Are General Population Utilities Appropriate to Use as Baselines for Age-Adjustment of Utility Values?

    Dec 1, 2023, 00:00

  • SA31 Systematic Versus Rapid Reviews: The Impact of Different Methodologies on the Reviews’ Conclusions

    Dec 1, 2023, 00:00

  • HTA304 The Impact of Different HTA Frameworks on Time to Patient Access: A Case Study Assessing the First Commercial Launch Indications for Lynparza, Tagrisso, Imfinzi, Calquence and Enhertu

    Dec 1, 2023, 00:00

  • EE688 Case for Clear Communication and Justification of Survival Extrapolation Methodology: A Review of NICE Submissions in Oncology

    Dec 1, 2023, 00:00

  • EPH147 The Costs of Unaddressed Hearing Loss in Chilean Children with Bilateral Microtia and External Auditory Canal Atresia and Cost Effectiveness of Different Treatment Interventions

    Dec 1, 2023, 00:00

  • HPR163 Underinvestment in Pharmaceutical Care and Unmet Pharmaceutical Needs Among Older European Adults

    Dec 1, 2023, 00:00

  • PCR107 (How) Should Cost-Effectiveness Analysis Accommodate Heterogeneity in Patient Preferences?

    Dec 1, 2023, 00:00

  • HPR12 Assessing COA Label Claims Based on Single-Arm Trials in Rare Diseases: A Review of US FDA Labels

    Dec 1, 2023, 00:00

  • HSD7 Longitudinal Analysis of Diagnostic Procedures for Sleep Disorders in the German In-Patient Sector

    Dec 1, 2023, 00:00

  • EE390 Optimizing the Use of Risk Factors to Guide the Cost-Effective Use of Palivizumab Prophylaxis Against Severe Respiratory Syncytial Virus Infection in Korean Infants Born 32–35 Weeks’ Gestational Age

    Dec 1, 2023, 00:00

  • MSR7 Incorporating External Data to Inform Overall Survival Extrapolation: A Review of NICE Health Technology Appraisals for Oncology Drugs

    Dec 1, 2023, 00:00

  • EE444 Cost-Effectiveness Analysis of Replacing PCV13 with PCV15 in the Pediatric National Immunization Program of Greece

    Dec 1, 2023, 00:00

  • EE584 Is Point-of-Care Testing in Emergency Departments Cost-Effective? A Systematic Literature Review

    Dec 1, 2023, 00:00

  • EE520 Hospital Costs in Resected Patients With Early-Stage Non-Small Cell Lung Cancer (NSCLC): A French Real-World Retrospective Study Based on the National Hospitalization Database (PMSI)

    Dec 1, 2023, 00:00

  • EPH143 Health Behavior and Quality of Life in Women With Endometriosis

    Dec 1, 2023, 00:00

  • HTA312 The Association of ESMO-Magnitude of Clinical Benefit Scale Scores and Subsidy Decisions of Targeted Therapies for Solid Tumors in Singapore

    Dec 1, 2023, 00:00

  • HTA79 CADTH Reimbursement Recommendations for Mental Illness Health Products: 10-Year Trends in Relation to Non-Mental Illness Health Products and Recommendations From Other HTA Bodies

    Dec 1, 2023, 00:00

  • Economic Evaluation

    Dec 1, 2023, 00:00

  • MSR148 Methodological Aspects of Composite Measures: A Comparison of Techniques for Rescaling and Aggregation

    Dec 1, 2023, 00:00

  • PT17 Modelling Treatment Duration in Psoriasis: Examining Extrapolation Approaches and Implications

    Dec 1, 2023, 00:00

  • HTA40 Making MCDA 'Shiny' With an Adaptive Support Tool for Healthcare Decision-Making: An Application in Broad Molecular Testing With R Shiny

    Dec 1, 2023, 00:00

  • EE151 Trade-Off between Comparators Comprehensiveness and Methodological Robustness in Cost-Utility Studies Reviewed By Has in France

    Dec 1, 2023, 00:00

  • EPH166 Access Trends to Cardiac Implantable Electronic Devices in the Brazilian Public Healthcare System: A Twelve-Year Real World Data Analysis

    Dec 1, 2023, 00:00

  • EE261 Economic Burden of Hemophilic Arthropathy in Patients with Hemophilia

    Dec 1, 2023, 00:00

  • EE43 Utilizing Real-World Evidence to Estimate Treatment Costs Among Norwegian Patients with Myasthenia Gravis Treated with Intravenous Immunoglobulin (IVIG)

    Dec 1, 2023, 00:00

  • EE111 Indirect Cost Burden for Individuals Living with Transfusion-Dependent Beta-Thalassemia in Europe

    Dec 1, 2023, 00:00

  • EE302 Value of End-of-Life Health Gains

    Dec 1, 2023, 00:00

  • PCR259 Patient-Reported Experience Along the Psoriatic Disease Patient Journey in Portugal

    Dec 1, 2023, 00:00

  • HPR56 Rare Disease Policies and Orphan Drug Designation Processes in European and Asia-Pacific (APAC) Countries

    Dec 1, 2023, 00:00

  • MSR60 Use of External Control Arms (ECAs) in Marketing Applications Submitted to European Medicines Agency (EMA): A Targeted Review

    Dec 1, 2023, 00:00

  • PCR84 The Daily Life and Psychosocial Impacts of Friedreich Ataxia: A Qualitative Study of Patient Lived Experiences

    Dec 1, 2023, 00:00

  • RWD125 A Health-Related Cost and Mortality Comparison Between Early and Late-Stage Lung Cancer: A Retrospective Cohort Study from a Brazilian Health Management Organization (HMO)

    Dec 1, 2023, 00:00

  • EE472 Estimation of the Burden of Chronic Kidney Disease in the Argentine Health System

    Dec 1, 2023, 00:00

  • MSR65 The Impact of Censoring Assumptions in the Generation of Individual Patient Data from Kaplan-Meier Estimates

    Dec 1, 2023, 00:00

  • PT27 How Much Does TLV Value Rarity? A Review of Reimbursement Decisions on Orphan Drugs in Sweden from 2017 through 2022

    Dec 1, 2023, 00:00

  • EPH81 Clinical Characteristics and Treatment Patterns of Patients With Early-Stage Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2023, 00:00

  • Award Winners

    Dec 1, 2023, 00:00

  • EPH148 Disease Burden of Sickle Cell Disease in Saudi Arabia

    Dec 1, 2023, 00:00

  • EE335 Burden of COVID-19 Related Hospitalization in Adults at High Risk for Severe Disease Progression in Germany—A Retrospective Claims Data Analysis

    Dec 1, 2023, 00:00

  • HSD104 Comparative Analysis of Legislations and Market Access of Cannabis Medicines in Poland and Ukraine

    Dec 1, 2023, 00:00

  • HPR92 Burnt Out or Something More? Investigating Drivers of and Spatial Variation in NHS Staff Turnover Intention

    Dec 1, 2023, 00:00

  • EE733 Distributional Cost-Effectiveness Analysis: A Case Study on Its Potential Prospects in HTA

    Dec 1, 2023, 00:00

  • EE72 A Cost-Effectiveness Analysis of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-Small Cell Lung Cancer in Portugal

    Dec 1, 2023, 00:00

  • RWD172 Strategies for the Rational Use of Biologic Therapies in an Integrated Clinic for Immune-Mediated Skin Diseases

    Dec 1, 2023, 00:00

  • EE477 Exploring the Perceived Value of Fixed-Dose Combinations in Type 2 Diabetes Mellitus in the EU4 and the UK

    Dec 1, 2023, 00:00
  • «
  • 21
  • 22 (current)
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • »